Skip to main content

Infertility Due to Azoospermia

2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

ReproNovo
ReproNovoSwitzerland - Lausanne
1 program
1
Leflutrozole, Dose 2Phase 1/21 trial
Active Trials
NCT07571928Not Yet Recruiting15Est. Aug 2027
Martin Pharmaceuticals
1 program
1
Leflutrozole, Dose 2Phase 1/2

Trial Timeline

Clinical trial activity over time

2026
2027
ReproNovoLeflutrozole, Dose 2

Clinical Trials (1)

Total enrollment: 15 patients across 1 trials

NCT07571928ReproNovoLeflutrozole, Dose 2

A Novel Aromatase Inhibitor, Leflutrozole, for Treatment of Non-Obstructive Azoospermia

Start: May 2026Est. completion: Aug 202715 patients
Phase 1/2Not Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.